Free Trial
NASDAQ:RNXT

RenovoRx Q3 2023 Earnings Report

RenovoRx logo
$1.08 +0.12 (+12.50%)
Closing price 03:59 PM Eastern
Extended Trading
$1.20 +0.12 (+10.65%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RenovoRx EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

RenovoRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

RenovoRx Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
8:30AM ET

Upcoming Earnings

RenovoRx's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Thursday, November 13, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

RenovoRx Earnings Headlines

RenovoRx (NASDAQ:RNXT) Upgraded by Wall Street Zen to Hold Rating
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
FY2025 EPS Estimates for RenovoRx Increased by HC Wainwright
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT), a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

View RenovoRx Profile

More Earnings Resources from MarketBeat